If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
152
results.
Updated on
25/04/2025 [06:56:00]
Results 75 to 100 of 152
Absstract of: US2025099674A1
Disclosed herein are systems and methods for transitioning between different CGM sensors in an infusion pump system with no loss in continuity of glucose levels between different sensor for use in closed loop diabetes therapy. Notifications can be provided to the user when a subsequent CGM sensor ought to be inserted, based on specific mechanics of the previous CGM sensor and of the anticipated subsequent CGM sensor. The system can further provide a notification when the subsequent CGM sensor is activated following the warm up period and capable of transmitting CGM data for use in the system and can prompt the user to or automatically transition the system from communicating with the previous sensor for CGM data to the subsequent sensor. Following the transition, the system may also notify the user that the previous CGM sensor can be removed from the user's body.
Absstract of: AU2023343209A1
Disclosed are techniques, devices and systems that provide adjustments to parameter settings of an insulin delivery algorithm based on inputs from a number of generic sensor devices. A majority of the generic sensor devices provide sensor readings that are unused as inputs to a drug deliver algorithm. The generic sensor devices may be operable to detect characteristics, such as changes in a state of a user. A processor may evaluate a sensor reading provided by a particular sensor with respect to a sensor baseline reading for the particular sensor. Using the result of the evaluation, the processor may calculate an adjustment to a parameter setting or settings of a medication delivery algorithm. A dosage of medication may be modified based on the adjustment of the parameter setting or settings.
Absstract of: WO2025064882A2
A system includes an analyte measurement system and a software application operatively coupled to the analyte measurement system. The analyte measurement system is configured to measure a ketone level in the bodily fluid of a patient. The application is configured to display at least one of (1) a current ketone level and an indicator of a current ketone trend, (2) a ketone trend graph, and (3) a total amount of time that the ketone levels are above at least one predetermined threshold level. The application is also configured to determine if the current ketone level is above the at least one predetermined threshold level, and in response to determining that the current ketone level is above the at least one predetermined threshold level, output an alarm, wherein the alarm is outputted periodically while the current ketone level is above the at least one predetermined threshold level.
Absstract of: WO2025060173A1
A personalized closed-loop artificial pancreas system, comprising: a measurement module (100) for continuously measuring the blood glucose level of a patient; an infusion module (102) for infusing insulin into the body of the patient; and a program module (101) for controlling the measurement module (100) and the infusion module (102). At least on the basis of the blood glucose level measured by the measurement module (100), the program module (101) generates an insulin infusion instruction, and controls the infusion module (102) to perform infusion; the program module (101) comprises a user interface; in response to the input of the patient, the program module (101) executes functions of corresponding meal patterns; the meal patterns comprise a high-carbohydrate pattern and a normal-carbohydrate pattern; and on the basis of the input of the patient, the program module (101) executes the function of the high-carbohydrate pattern or the normal-carbohydrate pattern. The present invention can be adapted to people having different carbohydrate consumption habits, improve the adaptability of a closed-loop artificial pancreas to different people, and enable people having different carbohydrate consumption habits to maintain a satisfactory blood glucose control effect.
Absstract of: AU2023271749A1
Disclosed are techniques, devices and computer products in which a processor is operable to access blood glucose measurement values and insulin data from a data memory. Based on the blood glucose measurement values the processor may be operable to identify high events that exceed an upper target blood glucose set point and low events in which blood glucose measurement values are below a lower target blood glucose set point. Rules may be applied to the high events and low events. Based on a result of the rules, high event patterns may be identified as well as a low event pattern. A respective pattern weight may be applied to each identified high event and each identified low and a graphical user interface may be populated with a number of high event patterns and for a number of low event patterns.
Absstract of: EP4527292A1
Provided is a body-attachable unit configured to be attached to and inserted into a body for measuring biometric information, the body-attachable unit including a housing formed so that a bottom surface is configured to be attached to skin, a printed circuit board (PCB) substrate, which is disposed in the housing, with a plurality of electrical contacts formed to protrude from a surface of the PCB substrate, and a sensor member including a sensor body part disposed in the housing and a sensor probe part formed and extended from a side of the sensor body part to protrude outward from the bottom surface of the housing and configured to be inserted into the skin if the housing is attached to the skin, and at least one of the plurality of electrical contacts is formed to make contact with the sensor body part to support the sensor body part, remaining of the plurality of electrical contacts are formed to be spaced apart from the sensor body part, and the sensor body part is to make contact with all of the plurality of electrical contacts by manipulation by a user.
Absstract of: EP4527291A2
A method and a system for improving the accuracy of a continuous glucose monitoring sensor by estimating a CGM signal at a time t+PH using a value of CGM at time t, using a short-time glucose prediction horizon to estimate the value of a CGM signal at a time t+PH with a noise estimation algorithm.
Absstract of: US2023301557A1
Embodiments of the present disclosure relate to systems, devices and methods for continuous glucose monitoring. In some embodiments, a continuous glucose monitoring (CGM) device is provided that includes a subcutaneous implantable electrochemical sensing probe (sensor). The sensor is planar and comprises counter and working electrodes that are deposited at both sides of the sensing probe. A biocompatible layer deposited at the entire sensor circumference minimizes inflammatory reaction. A reel to reel production process provides “per sensor” layers' deposition at predefined spots on a base sheet during displacement between production stations. Production processes are conducted initially at one side of the base sheet followed by production processes on the opposite side. Sensor by sensor working electrode surface areas and layers' thickness are measured and “per sensor” data (“dry” parameters) is stored according to base sheet identifiers that could be implemented by printed or etched markings or else by other means such as RFID. In addition, batch parameters are measured on a sample basis (in vitro “wet” parameters). A factory calibration algorithm analyzes “per lot” sample of sensors' performance (in vitro “wet” parameters in glucose solutions) as well as individual sensor measurement and combines the data in a calibration algorithm to calculate individual sensor calibration parameters and data is programmed back to the individual sensor.
Absstract of: EP4464242A2
The present disclosure provides apparatuses and methods for measuring capacitance as an indication of susceptibility to the formation of a diabetic foot ulcer.
Absstract of: WO2025055788A1
An OCTA-based non-invasive continuous blood glucose measurement method and apparatus. The OCTA-based non-invasive continuous blood glucose measurement method comprises: performing continuous OCT scanning imaging on a target tissue region, then using a depth attenuation characteristic of an OCT signal to extract a three-dimensional scattering coefficient of the target tissue region, and generating a three-dimensional microvascular distribution of the target tissue region; then accurately distinguishing a blood scattering coefficient and a tissue scattering coefficient on the basis of the three-dimensional scattering coefficient and the three-dimensional microvascular distribution; using an electrochemical method to measure reference blood glucose concentrations at two moments, and finally, respectively combining the reference blood glucose concentrations with the blood scattering coefficient and the tissue scattering coefficient to achieve continuous measurement of a blood glucose concentration and an interstitial fluid glucose concentration. According to the method, on the basis of OCTA guidance, the synchronous measurement of the interstitial fluid glucose concentration is implemented while accurate measurement of the blood glucose concentration is implemented, and the method has a great heuristic significance for the optical non-invasive blood glucose measurement.
Absstract of: WO2025055545A1
The present application provides an eardrum temperature measuring apparatus, a blood sugar measuring method, a system, and a device. By means of a high-precision eardrum temperature measuring apparatus measuring multiple temperature points disposed in the ear canal, a target eardrum temperature is estimated without contacting the eardrum; next, based on the target eardrum temperature, a target oral temperature is estimated on the basis of a pre-established correspondence relationship between eardrum and oral cavity temperatures; then, by means of a pre-calibrated invasive blood sugar value and an oral calibration temperature, a temperature correspondence relationship between a blood sugar increment and an oral temperature increment is established, and a target blood sugar increment can be calculated; finally, based on the target blood sugar increment and the pre-calibrated invasive blood sugar value, a target blood sugar value is calculated, that is, by means of the precision measuring apparatus and the conversion relationships between multiple pieces of precision data, the accuracy and stability of blood sugar measurement are improved, the influence of external factors on blood sugar measurement is reduced, and the ability of a measurement process to resist interference is improved.
Absstract of: WO2025055546A1
The present application provides a tympanic membrane temperature measuring apparatus, a blood glucose measuring method, a system, and a device. First, a target tympanic membrane temperature is acquired; a target oral cavity temperature is estimated on the basis of a pre-established temperature correspondence between the tympanic membrane and the oral cavity; a temperature correspondence between blood glucose increments and oral cavity temperature increments is then established on the basis of a pre-calibrated invasive blood glucose value and an oral cavity calibration temperature, so as to calculate a target blood glucose increment; and finally, a target blood glucose value is calculated on the basis of the target blood glucose increment and the pre-calibrated invasive blood glucose value. In this way, impact of other factors on blood glucose measurement is reduced while increasing the apparent temperature in the blood glucose measurement process.
Absstract of: US2025090053A1
The present invention relates to a body attachment unit for continuous blood glucose monitoring, in which a body attachment unit is manufactured so as to be assembled in an applicator, thereby minimizing additional work and allowing attachment of the body attachment unit to a body simply by operation of the applicator. In particular, a wireless communication chip is provided in the body attachment unit to enable communication with an external terminal, thereby enabling simple and convenient use without additional work of connecting a separate transmitter, and allowing easier maintenance. In addition, activation occurs by a user's operation after the body attachment unit is attached to the body, such that an activation start time can be adjusted to a time appropriate to the user's needs, and activation occurs in a stabilized state, thereby allowing more accurate blood glucose monitoring.
Absstract of: US2025090052A1
An aspect of an embodiment or partial embodiment of the present invention (or combinations of various embodiments in whole or in part of the present invention) comprises, but not limited thereto, a method and system (and related computer program product) for continually assessing the risk of hypoglycemia for a patient and then determining what action to take based on that risk assessment. A further embodiment results in two outputs: (1) an attenuation factor to be applied to the insulin rate command sent to the pump (either via conventional therapy or via open or closed loop control) and/or (2) a red/yellow/green light hypoglycemia alarm providing to the patient an indication of the risk of hypoglycemia. The two outputs of the CPHS can be used in combination or individually.
Absstract of: US2025090082A1
There is a need for more effective and efficient predictive data analysis, such as more effective and efficient data analysis solutions for performing predictive monitoring of the glucose-insulin endocrine metabolic regulatory system.
Absstract of: US2025090103A1
Conditions of pathophysiologic dysglycemia, associated with type 1 diabetes, can be detected early, including in children. Glycemia data is collected by continuous glucose monitoring devices connected to a cloud server. The server learns person-specific patterns of glycemia and trains a model accordingly, which may serve as a baseline for comparison or as the basis for prediction of future patterns. Such models are conditioned by risk factors and various concurrent activities such as exercise and consumption of sugars. Person-specific models trained at different time periods give different simulated patterns of glycemia. Deviations between the simulated patterns, or between the predicted and actual patterns, can indicate progression of pathophysiologic dysglycemia and type 1 diabetes. These models and comparisons can be further interpreted by the software to result in a reported recommendation for additional diagnostic testing or a reported conclusion of diagnosis and recommendation of preventative intervention.
Absstract of: US2025090753A1
Disclosed herein are techniques related to making trend based adjustments to insulin dosage. In some embodiments, the techniques may involve obtaining, based on glucose measurements performed on a person, a glucose value and a glucose rate of change (ROC). An initial insulin amount to deliver to the person is calculated based on this glucose value. However, an adjustment value can be obtained in response to a determination that the glucose value exceeds a glucose threshold, and that the glucose ROC exceeds an ROC threshold. The adjustment value represents an adjustment to be applied to the initial insulin amount when the glucose threshold and the ROC threshold are both exceeded. The adjustment value can be predetermined, based on earlier glucose measurements performed on the person. For instance, the adjustment value and the thresholds can be jointly determined through a computer simulation using a person-specific physiological model.
Absstract of: US2025090758A1
A botulinum toxin syringe having a barrel has volumetric marking graduations scaled at four units per 0.1 mL. These volumetric marking graduations allow for ease of unit conversion and can reduce the likelihood of overdosing or under dosing of botulinum toxin. The syringe may further comprise further volumetric marking graduations configured to be interchangeably used for administration of insulin or botulinum toxin. The syringe may further comprise further volumetric marking graduations configured for interchangeably use for administration of different types of botulinum toxin.
Absstract of: US2025094109A1
A continuous glucose monitor for wirelessly transmitting data relating to glucose value to a plurality of displays is disclosed, as well as systems and methods for limiting the number of display devices that can connect to a continuous glucose transmitter. In addition, security, including hashing techniques and a changing application key, can be used to provide secure communications between the continuous glucose transmitter and the displays. Also provided is a continuous glucose monitor and techniques for authenticating multiple displays, providing secure data transmissions to multiple displays, and coordinating the interaction of commands and data updates between multiple displays.
Absstract of: US2025095869A1
Presented herein is a handheld analyte measurement device. The analyte measurement device includes one or more software applications to help the user manager their diabetes. Embodiments and descriptions of the various applications are provided below in conjunction with the handheld analyte measurement device.
Absstract of: US2025095862A1
In some examples, an apparatus, such as a mobile phone can include an input module such as a touch screen, a camera, a processor, and computer readable medium. The camera captures one or more images of a person. The processor can use a single machine learning model to estimate the human body features of the person based on the captured images, and use the human body features to generate a disease risk assessment value associated with diabetes and cardiovascular disease risks. The human body features can include at least one or more of: 3D body shape, or body shape indicators; and one or more of: blood flow, blood pressure, heart rate, respiratory rate, heart rate variability, cardiac workload, irregular heartbeats, or stress index. The machine learning model can be trained over a set of training images.
Absstract of: AU2025201387A1
A system, a method, and a computer program product for providing wearable continuous blood glucose monitoring. In some embodiments, there is provided a method that includes receiving, at a smartwatch, an alert representative of a glucose state of a host-patient coupled to a glucose sensor; detecting, at the smartwatch, a predetermined action indicative of a request to generate a glance view providing an indication of the glucose state of the host-patient; and presenting, at the smartwatch and in response to the detecting, the glance view providing the indication of the glucose state of the host-patient.
Absstract of: US2025090754A1
Embodiments can relate to an insulin delivery controller which implements a processor configuration to efficiently attain an insulin delivery target. The insulin delivery controller can include a processor and a memory associated with the processor. The processor can process glucose data received from the memory, including a data representation of glycemic disturbance (d(t)). The processor can determine a glucose rate of change (G′(t)). The processor can generate a command signal to dynamically reshape a glycemic disturbance within a prediction horizon of the insulin delivery controller according to the G′(t). The processor can generate an insulin command signal for an insulin delivery unit to adjust an insulin delivery dosage amount and/or an insulin delivery dosage rate.
Absstract of: EP4523621A2
A method for providing blood glucose data is provided. In response to a suspension of a continuous basal insulin delivery, by an insulin delivery pump, the method identifies a condition indicating continuing hypoglycemia that continues when basal insulin delivery is suspended; and performs an action, by the insulin delivery pump, based on identifying the condition.
Nº publicación: US12251242B1 18/03/2025
Applicant:
UPDOC INC [US]
UpDoc Inc
Absstract of: US12251242B1
An artificially intelligent, voice-based method for prescribing, managing and administering at least one medication for management of type 2 diabetes to a patient. Aspects of the present disclosure provide for a system and method for configuring one or more clinical algorithms according to one or more clinical protocols to configure a conversational AI model. The conversational AI model is configured to drive a conversational AI agent configured to facilitate a plurality of multi-turn conversational interactions between a patient user and the conversational agent to enable automated initiation and titration of one or more diabetes medications for the patient.
BOPI
Electronic site
